公开(公告)号：EP3274091A1

公开(公告)日：2018-01-31

申请号：EP16769605.3

申请日：2016-03-23

申请人： The University of North Carolina at Chapel Hill ,  Cornell University ,  Board of Supervisors of Louisiana State University And Agricultural and Mechanical College

发明人： SOPER, Steven, A. ,  BARANY, Francis ,  PARK, Sunggook ,  MURPHY, Michael ,  MCKINNEY, Collin, J. ,  EFCAVITCH, John, William ,  HUPERT, Mateusz

IPC分类号： B01L1/00 ,  B01L99/00 ,  C40B30/04 ,  C12M1/40 ,  G01N33/483 ,  G01N33/569

CPC分类号： G01N33/48721 ,  B01L3/5027 ,  B01L3/502715 ,  B01L3/502753 ,  B01L3/502761 ,  B01L2200/0647 ,  B01L2300/0645 ,  B01L2300/0861 ,  B01L2300/0896 ,  C12M1/40 ,  C12M23/16 ,  C12Q1/6806 ,  C12Q1/6837 ,  C12Q1/6869 ,  C12Q1/6874 ,  C12Q2561/125 ,  C12Q2565/629 ,  C12Q2565/631

摘要： The present invention is directed to a device that comprises a biomolecular processor and one or more nanotubes. Each biomolecular processor comprises a bioreactor chamber defined by a solid substrate, a plurality of spaced support structures within said bioreactor chamber and attached to the solid substrate, and one or more capture molecules immobilized to some or all of said plurality of spaced support structures, said one or more capture molecules suitable to bind to a portion of a target nucleic acid molecule in a sample. The device also comprises one or more nanotubes defined by the solid substrate and fluidically coupled to the bioreactor chamber.

公开(公告)号：EP2588133B1

公开(公告)日：2018-01-17

申请号：EP11730833.8

申请日：2011-06-29

申请人： Intervet International B.V. ,  Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

发明人： O'CONNELL, Kevin, A. ,  RAMACHANDRA, Rangappa, Narayana ,  GAUNT, Stephen, David ,  CORSTVET, Richard, E. ,  WASMOEN, Terri, Lee

IPC分类号： A61K39/02 ,  C12R1/01

CPC分类号： A61K39/0233 ,  A61K2039/521 ,  A61K2039/552 ,  A61K2039/55511 ,  A61K2039/57 ,  C12R1/01

摘要： Vaccine and/or immunogenic compositions that comprise an effective immunizing amount of an antigen from E. canis are described. In addition, methods of immunizing a subject against E. canis by providing the vaccine and/or immunogenic compositions are also disclosed.

公开(公告)号：EP2297175B1

公开(公告)日：2013-08-07

申请号：EP09759412.1

申请日：2009-06-04

申请人： Uniwersytet Warszawski ,  Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

发明人： KOWALSKA, Joanna ,  JEMIELITY, Jacek ,  DARZYNKIEWICZ, Edward ,  RHOADS, Robert, E. ,  LUKASZEWICZ, Maciej ,  ZUBEREK, Joanna

IPC分类号： C07H21/00 ,  C07H21/02

CPC分类号： C07H21/00 ,  C07H21/02 ,  C12N15/67 ,  C12P21/02

公开(公告)号：EP2209471A2

公开(公告)日：2010-07-28

申请号：EP08845477.2

申请日：2008-10-30

申请人： The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

发明人： BAZAN, Nicolas, G. ,  HE, Jiu-Cheng ,  BAZAN, Haydee, E. P.

IPC分类号： A61K31/232 ,  A61P27/02

CPC分类号： A61K31/232 ,  A01N1/02 ,  A01N1/0226 ,  A61K45/06 ,  A61K2300/00

摘要： Lipoxin A4 and its analogs have been discovered to promote the cell proliferation of cornea endothelial cells, and thus promote the proper functioning of the labile tissue layer of cornea endothelial cells. These lipoxin compounds can be administered alone or in combination with other known compounds as a solution that can be topically administered to decrease the swelling of the cornea or maintain the clarity of the cornea. Lipoxin A4 or its analogs can also be combined with other known nutritive compounds to form a solution for storage of a cornea prior to transplantation.

摘要翻译： 脂氧素A4及其类似物已被发现可促进角膜内皮细胞的细胞增殖，从而促进角膜内皮细胞的不稳定组织层的正常功能。 这些脂氧素化合物可以单独或与其他已知化合物组合施用，作为可以局部施用以减少角膜肿胀或保持角膜透明度的溶液。 脂氧素A4或其类似物也可以与其他已知的营养化合物组合以形成用于在移植之前储存角膜的溶液。

公开(公告)号：EP2167523A2

公开(公告)日：2010-03-31

申请号：EP08771474.7

申请日：2008-06-19

申请人： Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College ,  University of Warsaw

发明人： JEMIELITY, Jacek ,  GRUDZIEN-NOGALSKA, Ewa, M. ,  KOWALSKA, Joanna ,  DARZYNKIEWICZ, Edward ,  RHOADS, Robert, E.

IPC分类号： C07H19/207

CPC分类号： C07H19/207 ,  C12P19/34 ,  C12P21/02

摘要： New RNA cap analogs are disclosed containing one or more phosphorothioates groups. The analogs also contain modifications at the 2′-O position of 7-methylguanosine that prevent them from being incorporated in the reverse orientation during in vitro synthesis of mRNA and that hence are “anti-reverse cap analogs” (ARCAs). The ARCA modification ensures that the S atom is precisely positioned within the active sites of cap-binding proteins in both the translational and decapping machinery. The new S-ARCA analogs are resistant to in vivo decapping enzymes. Some S-ARCAs have a higher affinity for eIF4E than the corresponding analogs not containing a phosphorothioate group. When mRNAs containing the various S-ARCAs are introduced into cultured cells, some are translated as much as five-fold more efficiently than mRNAs synthesized with the conventional analog m7GpppG.

公开(公告)号：EP1578436B1

公开(公告)日：2010-03-31

申请号：EP03814232.9

申请日：2003-12-18

申请人： BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE

发明人： KOOCHEKPOUR, Shahriar ,  SARTOR, Olivier, A.

IPC分类号： A61K38/00

CPC分类号： C07K14/475 ,  A61K38/00 ,  C07K14/415 ,  C07K2319/01

公开(公告)号：EP2144632A2

公开(公告)日：2010-01-20

申请号：EP08755220.4

申请日：2008-05-09

申请人： Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

发明人： KOUSOULAS, Konstantin G.

IPC分类号： A61K48/00 ,  A61K39/245 ,  C12N7/01

CPC分类号： C07K14/005 ,  A61K35/763 ,  C12N7/00 ,  C12N2710/16622 ,  C12N2710/16632 ,  C12N2710/16662

摘要： A recombinant herpes simplex virus type-1 (HSV-1) has been constructed that carries a deletion of one of the two viral gamma1 34.5 genes and other immediate early genes, which render the virus able to selectively replicate in cancer cells but not efficiently replicate in normal cells, and in which specific mutations have been introduced to enable the virus to spread among cancer cells by virus-induced fusion. Specifically, syncytial mutations have been introduced in the genes coding for glycoprotein B and glycoprotein K of the virus, enabling high replication and spread of the virus in cancer cells in the presence of substantially lower amounts of gamma1 34.5 protein, which is required for optimum infectious virus produced and virus-induced cell fusion. These altered viruses or the isolated bacterial chromosomes could be used to treat various cancers including breast, liver, colon, and other tissues.

公开(公告)号：EP2086361A2

公开(公告)日：2009-08-12

申请号：EP06850514.8

申请日：2006-10-04

申请人： Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College

发明人： DELLINGER, Harold, B. ,  LOMNICKI, Slawomir, M.

IPC分类号： A24D3/16 ,  A24B15/18 ,  A24D3/02

CPC分类号： A24D1/002 ,  A24B15/28 ,  A24B15/286 ,  A24B15/287 ,  A24B15/288 ,  A24D3/16

摘要： Catalysis is used to reduce levels of radicals, other toxins, and carbon monoxide in cigarette smoke. The catalysis operates efficiently at temperatures typical of tobacco smoke, is formed from nontoxic materials, and is relatively inexpensive. The nanostructured catalyst contains titanium oxide, iron oxide, and calcium oxide. The catalyst comprises a layer of iron oxide in the y form supported on a titanium oxide core. Addition of calcium cations helps to stabilize the iron oxide in the y form. The iron oxide layer is on the order of a few nanometers thick on the surface of the titanium oxide core, in an 'egg-in-shell' structure. The nanocatalyst is highly active in promoting the oxidation of compounds such as hydroquinone, catechol, other hydrocarbons, chlorinated phenols, semiquinone radicals, and carbon monoxide, at room temperature and higher temperatures. Catalysis remains active in a pyrolytic or combustion environment for extended periods of time, and has high redox cycling potential. The efficiency of catalysis is not strongly affected by coking in a pyrolytic or combustion environment.

公开(公告)号：EP2074996A1

公开(公告)日：2009-07-01

申请号：EP09157996.1

申请日：2003-11-12

申请人： The Board of Supervisors of Louisiana State University and Agricultural and Mechanical College

发明人： Bazan, Nicolas G. ,  Sunkel, Carlos ,  Builla, Julio Alvarez ,  Paul, Dennis

IPC分类号： A61K31/428 ,  A61K31/485 ,  A61P25/04

CPC分类号： A61K45/06

摘要： The present invention relates to pharmaceutical combinations of opioid and non-opioid analgesics in an intimate admixture with an analgesic from a series of N-acylated 4-hydroxyphenlyamine derivatives, linked via an alkylene bridge to the nitrogen atom of a 1,2-benzisothiazol-3 (2H)-one 1, 1-dioxide group and methods for their use to alleviate pain in mammals. The analgesic combinations exhibit enhanced analgesic potency, do not suppress blood coagulation, and have little hepatotoxic effect.

摘要翻译： 本发明涉及与通过亚烷基桥连接到1,2-苯并异噻唑-2-酮的氮原子连接的一系列N-酰化4-羟基苯胺基衍生物与镇痛剂紧密混合的阿片样物质和非阿片样物质镇痛药的药物组合， 3（2H） - 酮1,1-二氧化物及其用于减轻哺乳动物疼痛的方法。 镇痛组合显示出增强的止痛效力，不抑制血液凝固，并且肝毒作用小。

公开(公告)号：EP1592789B1

公开(公告)日：2009-05-20

申请号：EP03800225.9

申请日：2003-12-24

申请人： TransGenRx, Inc. ,  THE BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE

发明人： COOPER, Richard, K. ,  FIORETTI, William, C. ,  CADD, Gary G.

IPC分类号： C12N15/00 ,  C12N15/63 ,  C12P21/00 ,  A01K67/027

CPC分类号： C12N15/8509 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/105 ,  A01K2227/30 ,  A01K2267/01 ,  A23L15/00 ,  A23V2002/00 ,  A61K39/00 ,  A61K48/00 ,  A61K2039/505 ,  C07K14/62 ,  C07K16/00 ,  C07K16/02 ,  C07K16/1063 ,  C07K16/26 ,  C07K2317/23 ,  C07K2317/34 ,  C12N15/85 ,  C12N2800/90 ,  C12N2830/003 ,  C12N2830/008 ,  C12N2830/90 ,  C12N2840/20 ,  Y02A50/407 ,  Y02A50/469 ,  A23V2300/21

摘要： Administration of modified transposon-based vectors has been used to achieve stable incorporation of exogenous genes into animals. These transgenic animals produce transgenic progeny. Further, these transgenic animals produce large quantities of desired molecules encoded by the transgene. Transgenic egg-laying animals produce large quantities of desired molecules encoded by the transgene and deposit these molecules in the egg.